M Zimecki1, J Artym, G Chodaczek, M Kocieba, M L Kruzel. 1. Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
Abstract
OBJECTIVE AND DESIGN: Previous studies demonstrated that lactoferrin (LF), given intravenously (i.v.), 24 h before lethal Escherichia coli ( E. coli) infection, protects mice against mortality. The aim of this investigation was to determine whether downregulation of serum TNF alpha activity and increase of neutrophil number in the circulation and bone marrow by LF could contribute to the protective action of LF against E. coli-induced sepsis. MATERIAL AND SUBJECTS: CBA female mice, 10-12 week old, weight 20-22 g, were used. TREATMENT: Mice were given 10 mg LF i.v. either 2 h or 24 h before i.v. administration of lethal dose of E. coli (5 x 10(8)). METHODS: Serum activities of TNF alpha and IL-1 were determined by bioassays 2 h following E. coli or LF injection. The blood and bone marrow smears were stained with Giemsa and May-Grünwald reagents and reviewed histologically. RESULTS: LF given 24 h before E. coli caused a 60% reduction of TNF alpha released into circulation. However, pretreatment of mice with LF 2 h before bacterial challenge resulted in strong (15 fold) increase of TNF alpha serum level. Analysis of bone marrow cell composition revealed a significant increase in neutrophil lineage cell content (myelocytes, bands and mature neutrophils) following 24 h pretreatment with LF (51.8% of the total cell count), versus PBS control (32.7%) and 2 h LF pretreatment (35.8%). The percentage of neutrophils (bands and mature forms) in the peripheral blood rose to 47.4% versus 32% and 32%, respectively. Intravenous administration of LF increased also interleukin 1 (IL-1) concentration in the circulation of noninfected mice. CONCLUSIONS: This investigation has added more information regarding the mechanism of the protective action of LF in E. coli-induced bacteremia by revealing the phenomenon of accelerated neutrophil recruitment and down-regulation of E. coli-induced TNF alpha serum level.
OBJECTIVE AND DESIGN: Previous studies demonstrated that lactoferrin (LF), given intravenously (i.v.), 24 h before lethal Escherichia coli ( E. coli) infection, protects mice against mortality. The aim of this investigation was to determine whether downregulation of serum TNF alpha activity and increase of neutrophil number in the circulation and bone marrow by LF could contribute to the protective action of LF against E. coli-induced sepsis. MATERIAL AND SUBJECTS: CBA female mice, 10-12 week old, weight 20-22 g, were used. TREATMENT: Mice were given 10 mg LF i.v. either 2 h or 24 h before i.v. administration of lethal dose of E. coli (5 x 10(8)). METHODS: Serum activities of TNF alpha and IL-1 were determined by bioassays 2 h following E. coli or LF injection. The blood and bone marrow smears were stained with Giemsa and May-Grünwald reagents and reviewed histologically. RESULTS: LF given 24 h before E. coli caused a 60% reduction of TNF alpha released into circulation. However, pretreatment of mice with LF 2 h before bacterial challenge resulted in strong (15 fold) increase of TNF alpha serum level. Analysis of bone marrow cell composition revealed a significant increase in neutrophil lineage cell content (myelocytes, bands and mature neutrophils) following 24 h pretreatment with LF (51.8% of the total cell count), versus PBS control (32.7%) and 2 h LF pretreatment (35.8%). The percentage of neutrophils (bands and mature forms) in the peripheral blood rose to 47.4% versus 32% and 32%, respectively. Intravenous administration of LF increased also interleukin 1 (IL-1) concentration in the circulation of noninfected mice. CONCLUSIONS: This investigation has added more information regarding the mechanism of the protective action of LF in E. coli-induced bacteremia by revealing the phenomenon of accelerated neutrophil recruitment and down-regulation of E. coli-induced TNF alpha serum level.
Authors: Michał Zimecki; Jolanta Artym; Maja Kocięba; Katarzyna Kaleta-Kuratewicz; Piotr Kuropka; Jan Kuryszko; Marian Kruzel Journal: Stem Cells Dev Date: 2013-08-24 Impact factor: 3.272
Authors: S K Velusamy; R Poojary; R Ardeshna; Waad Alabdulmohsen; D H Fine; K Velliyagounder Journal: Antimicrob Agents Chemother Date: 2013-11-04 Impact factor: 5.191
Authors: Maria Elisa Drago-Serrano; Rafael Campos-Rodríguez; Julio César Carrero; Mireya de la Garza Journal: Int J Mol Sci Date: 2017-03-01 Impact factor: 5.923
Authors: Penghua Yang; Jianwu Wang; Guochun Gong; Xiuzhu Sun; Ran Zhang; Zhuo Du; Ying Liu; Rong Li; Fangrong Ding; Bo Tang; Yunping Dai; Ning Li Journal: PLoS One Date: 2008-10-20 Impact factor: 3.240